Physician profile
Rituben Patel
NPI 1720789696
$4,309.38
in general payments reported to CMS, 2019-2025
28 companies · $1,487 in 2025
The $1,487 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14.49 · 2023: $1,093 · 2024: $1,714 · 2025: $1,487.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,295.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,294.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $599.80 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $529.48 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Novo Nordisk INC | $492.66 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $455.01 | 2023-2025 | |
| Lilly USA, LLC | $394.96 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $348.80 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $210.70 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $182.12 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $161.81 | 2023-2025 | Pifeltro, Capvaxive, Delstrigo |
| Amgen INC. | $116.16 | 2023-2025 | Evenity, Krystexxa, Repatha |
| Lexicon Pharmaceuticals, INC. | $102.81 | 2023-2024 | Inpefa |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.72 | 2023-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $93.67 | 2023-2024 | Fanapt, Hetlioz |
| Lundbeck LLC | $63.63 | 2024-2025 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $55.86 | 2023-2024 | Jardiance, Tradjenta |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.11 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $48.78 | 2023-2024 | Rexulti |
| Noven Therapeutics, LLC | $48.63 | 2024 | Xelstrym |
| Astellas Pharma US INC | $45.34 | 2025 | Veozah |
| Inspire Medical Systems, INC. | $44.01 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $32.05 | 2024 | Austedo Xr |
| Baxter Healthcare | $29.93 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Avion Pharmaceuticals | $21.62 | 2023 | Methylphenidate Hydrochloride |
| Phathom Pharmaceuticals, INC. | $17.65 | 2024 | Voquezna |
| Esperion Therapeutics, INC. | $15.73 | 2024 | Nexletol |
| Janssen Pharmaceuticals, INC | $15.51 | 2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $15.50 | 2023 | Trintellix |
| Idorsia Pharmaceuticals US INC | $13.33 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rituben Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.